TOPLINE:

Oral vancomycin was effective in achieving clinical and biochemical remission in paediatric patients with non- primary sclerosing cholangitis (PSC) inflammatory bowel disease (IBD), enabling almost half of the participants to reduce or stop other treatments. The treatment showed the greatest benefit among patients with mildly active ulcerative colitis (UC) and IBD unclassified (IBDU).

METHODOLOGY:

Researchers conducted a retrospective study at a hospital in Edinburgh and included 31 paediatric patients (median age at diagnosis, 13.1 years; 52% boys) with IBD who started on oral vancomycin at any point during their illness for active luminal colonic disease and/or drug dependency between January 2017 and August 2024.

Patients weighing 30 kg or more received oral vancomy

See Full Page